Results 91 to 100 of about 19,663 (194)

Cancer Neuroscience: From Local Neuro–Immune Microenvironments to Systemic Brain–Body Circuitry

MedComm, Volume 7, Issue 9, September 2026.
This review outlines the cancer neuroscience paradigm, spanning systemic brain–body circuitry and local neuro–immune–tumor microenvironments. We discuss how tumors promote axonogenesis and pseudo‐synapse formation, and how sensory neuropeptides, such as CGRP, contribute to CD8+ T‐cell exhaustion.
Mingxuan Xie, Yu Zhao, Xinruo Xing, Yuqiang Liu, Jungang Zhao, Maojin Yao, Jun Tang, Jianzhu Zhao   +7 more
wiley   +1 more source

Overcoming Chemoresistance in Cancer: The Promise of Crizotinib [PDF]

Chemoresistance is a major obstacle in cancer treatment, often leading to disease progression and poor outcomes. It arises through various mechanisms such as genetic mutations, drug efflux pumps, enhanced DNA repair, and changes in the tumor ...
Musa, Sanaa, Wang, Junbiao, Mahajna, Jamal, Jamal Mahajna, Junbiao Wang, Cristina Marchini, Agbarya, Abed, Selawi, Adan, Adan Selawi, Marchini, Cristina, Amara, Noor, Abed Agbarya, Sanaa Musa, Noor Amara   +13 more
core   +1 more source

Complex renal cysts associated with crizotinib treatment [PDF]

, 2015
An apparent causal association between crizotinib treatment and renal cyst development emerged during clinical trials in anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC). Serious adverse event (SAE) reports of renal cysts from
Cynthia H. Bartlett, Wilner, KD, Tanaka, K, Allan Safferman, Tang, Y, Han, JY, Tassell, V, Lee, GK, Geon Kook Lee, Benjamin J. Solomon, Bartlett, CH, Safferman, A, Tan, W, Shaw, AT, Lee, SH, Yiyun Tang, Weiwei Tan, Schnell, P, Kaoru Tanaka, Keith D. Wilner, de Pas, T, Alice T. Shaw, Ji‐Youn Han, Tommaso de Pas, Patrick Schnell, Solomon, BJ, Vanessa Tassell, Soo‐Hyun Lee   +27 more
core   +1 more source

A Case of Orbital Metastasis as Disease Progression of Anaplastic Lymphoma Kinase-Positive Lung Cancer Treated with Crizotinib

Case Reports in Oncology, 2015
Orbital metastasis of lung cancer is rare. It often causes visual disorder. To date, there are only a few case reports. Crizotinib is an anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor that leads to responses in most patients with ALK-positive
Yoshihiko Sakata, Kodai Kawamura, Kazuya Ichikado, Masakazu Yoshioka   +3 more
doaj   +1 more source

Traditional Chinese Medicine for lung cancer: Mechanisms, clinical evidence, and future perspectives

Precision Medical Sciences, Volume 15, Issue 3, Page 206-226, September 2026.
Graphical abstract represents the risk factors for lung cancer, TCM efficacy and clinical outcomes to future challenges. Abstract Lung cancer remains a leading cause of global cancer mortality. Despite advances in conventional treatments such as surgery, chemotherapy, targeted therapy, and immunotherapy, challenges including drug resistance, toxicity ...
Zhangdeng Chen, Liujun Bao
wiley   +1 more source

Development of crizotinib-associated renal cyst in a non-small cell lung cancer patient with ALK fusion: a case report and review of the literature

Diagnostic Pathology
Background Crizotinib, an oral first-generation tyrosine kinase inhibitor (TKI), is superior to systemic chemotherapy for the treatment of non-small cell lung cancer (NSCLC) with positive rearrangement of anaplastic lymphoma kinase (ALK).
Peng Zhang, JiaHua Xu, Qing Wu, Jianxin Qian, Song Wang   +4 more
doaj   +1 more source

Successful Crizotinib Rechallenge after Crizotinib-Induced Organizing Pneumonia in Anaplastic Lymphoma Kinase-Rearranged Non-Small Cell Lung Cancer

, 2014
Crizotinib, a first-line anaplastic lymphoma kinase (ALK)-tyrosine kinase inhibitor, has shown promising results for the treatment of locally advanced and metastatic lung cancer presenting the ALK rearrangement.
Akihito Kubo, Nobuhiro Asai, Toyoharu Yokoi, Etsuro Yamaguchi   +3 more
core   +1 more source

Identification of Novel Therapeutic Agent Candidates Through High Throughput Screening With Chemical Library Based on Molecular Subclassification in Canine Histiocytic Sarcoma Cell Lines

Veterinary and Comparative Oncology, Volume 24, Issue 3, Page 554-567, September 2026.
ABSTRACT Effective chemotherapy for canine histiocytic sarcoma (CHS) has yet to be established. In our previous study, CHS cell lines were subclassified into two groups based on their gene expression profiles: Group A and Group B. This study aimed to identify novel therapeutic agents that are effective against each CHS subgroup, and we performed high ...
Hiroki Sakuma, Hirotaka Tomiyasu, Mari Takamiya, Yuko Goto‐Koshino, Atsushi Tsukamoto, Makoto Bonkobara, Masaru Okuda   +6 more
wiley   +1 more source

Crizotinib in the treatment of non--small-cell lung cancer.

, 2013
An anaplastic lymphoma kinase (ALK) translocation giving rise to activated ALK tyrosine kinase is present in approximately 5% of non-small-cell lung cancers (NSCLCs).
Rothschild SI, Gautschi O
core   +1 more source

Efficacy and safety of crizotinib in patients with anaplastic lymphoma kinase-positive advanced-stage non-small-cell lung cancer

, 2018
Ahmed Mohieldin,1,2 Ayman Rasmy,1,3,4 Mohamed Ashour,2,5 Muath Al-Nassar,6 Rola H Ali,7,8 Fahad G El-Enezi6 1Medical Oncology, Zagazig University Hospitals, Zagazig, Egypt; 2Medical Oncology Department, Sheikha Badriya Alsabah Centre, Kuwait Cancer ...
El-Enezi FG, Ali RH, Ashour M, Mohieldin A, Rasmy A, Al-Nassar M   +5 more
core